Kiniksa Pharmaceuticals International, plc
KNSA
$56.51
-$2.03-3.47%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 754.05M | 677.56M | 597.97M | 529.33M | 481.17M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 754.05M | 677.56M | 597.97M | 529.33M | 481.17M |
| Cost of Revenue | 341.93M | 307.22M | 282.33M | 248.18M | 219.50M |
| Gross Profit | 412.11M | 370.35M | 315.65M | 281.15M | 261.67M |
| SG&A Expenses | 213.89M | 196.27M | 180.03M | 177.33M | 172.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 660.83M | 600.34M | 559.82M | 524.86M | 496.97M |
| Operating Income | 93.22M | 77.22M | 38.15M | 4.48M | -15.80M |
| Income Before Tax | 105.98M | 88.87M | 48.62M | 14.26M | -6.31M |
| Income Tax Expenses | 32.93M | 29.86M | 12.70M | 9.47M | 10.64M |
| Earnings from Continuing Operations | 73.06 | 59.01 | 35.92 | 4.79 | -16.95 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 73.06M | 59.01M | 35.92M | 4.79M | -16.95M |
| EBIT | 93.22M | 77.22M | 38.15M | 4.48M | -15.80M |
| EBITDA | 94.89M | 78.78M | 39.64M | 5.98M | -14.23M |
| EPS Basic | 0.97 | 0.79 | 0.48 | 0.06 | -0.24 |
| Normalized Basic EPS | 0.88 | 0.75 | 0.41 | 0.12 | -0.06 |
| EPS Diluted | 0.91 | 0.75 | 0.45 | 0.04 | -0.25 |
| Normalized Diluted EPS | 0.82 | 0.70 | 0.38 | 0.10 | -0.06 |
| Average Basic Shares Outstanding | 300.64M | 296.77M | 293.12M | 290.13M | 287.70M |
| Average Diluted Shares Outstanding | 321.95M | 315.69M | 306.44M | 298.13M | 291.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |